HealthInvest Partners’s Autolus Therapeutics AUTL Stock Holding History

HealthInvest Partners’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,169,634	Closed	-$2.33M	–	41
2025 Q4	$2.33M	Hold	1,169,634	–	–	0.74%	36
2025 Q3	$1.91M	Buy	1,169,634 +64,173	+6%	+$125K	0.75%	35
2025 Q2	$2.52M	Buy	1,105,461 +625,817	+130%	+$1.03M	1.08%	29
2025 Q1	$743K	Hold	479,644	–	–	0.33%	35
2024 Q4	$1.06M	Buy	479,644 +37,221	+8%	+$126K	0.5%	32
2024 Q3	$1.61M	Buy	442,423 +216,278	+96%	+$863K	0.75%	29
2024 Q2	$787K	Buy	226,145 +129,800	+135%	+$560K	0.48%	33
2024 Q1	$615K	Hold	96,345	–	–	0.37%	41
2023 Q4	$620K	Buy	+96,345	New	+$367K	0.49%	39

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HealthInvest Partners's AUTL Position: Q1 2026 in Review

HealthInvest Partners sold out of Autolus Therapeutics (AUTL) in Q1 2026, closing a stake of 1,169,634 shares — an estimated $2.33M sold.

HealthInvest Partners first reported a position in AUTL in Q4 2023 and held it in 9 quarters. The position peaked at $2.52M in Q2 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q1 2026.

HealthInvest Partners reported no remaining Autolus Therapeutics position as of Q1 2026 after selling out during the quarter.
HealthInvest Partners sold 1,169,634 Autolus Therapeutics shares in Q1 2026, an estimated $2.33M.
HealthInvest Partners first reported a position in Autolus Therapeutics in Q4 2023 and held it in 9 quarters.
HealthInvest Partners's Autolus Therapeutics position peaked at $2.52M in Q2 2025.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2026.

Based on HealthInvest Partners's 13F filing for Q1 2026, filed 11 May 2026.